May 2, 2003 - A retrospective study and results of a phase 3 trial point to new approaches to both short-term cardioversion and long-term maintenance of patients with atrial fibrillation (AF).

The oral anticoagulant rivaroxaban is a safe and effective alternative to vitamin K antagonists for patients with atrial fibrillation (AF) undergoing cardioversion. This finding from the X-VeRT trial ...

BARCELONA, Spain—Apixaban appears to be an effective and safe alternative to heparin plus a vitamin K antagonist (VKA) for patients with A-fib who are undergoing rapid cardioversion and require ...

A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...